Abstract 332MO
Background
To compare long-term toxicity incidences, including secondary cancer (Sec.ca) with or without TBI, in Asian patients receiving allogeneic hematopoietic stem cell transplantation (HSCT) using a nationwide database.
Methods
We identified 4,554 patients receiving HSCT for leukemic disease from 2009 to 2016 using the Healthcare Bigdata system of Korea. Incidence rate ratios (IRRs) for Sec.Ca, cataracts, hypothyroidism, chronic kidney disease (CKD), myocardial infarctions (MIs), or strokes were compared, and standardized incidence ratios (SIR) of Sec.ca was also estimated.
Results
TBI was conducted on 1,409 patients (30.9%). No overall survival differences based on TBI were observed. With a median follow-up duration of 58.2 months, 143 patients were diagnosed with subsequent Sec.Ca (3.4%). Incidence rates per 1000 Person-Year (95% CI) were 6.56(4.75–8.84) and 7.23(5.89–8.80) in the TBI and no-TBI groups, respectively (p=.594). Also, the SIR (95% CI) was not significantly increased by TBI [1.32(0.86–1.94) vs. 1.39(1.08–1.77) in the no-TBI group]. In the young age group (0-19 years), SIRs were increased in both groups regardless of TBI (8.60 vs. 11.96). The IRRs (95% CI) of cataracts [1.60(1.30–1.95)], CKD [1.85(1.31–2.62)], and hypothyroidism [1.50(1.07–2.09)] were significantly increased after TBI. However, there were no significant differences in the occurrence of MI and stroke according to TBI.
Conclusions
Our results suggest that modern TBI may not additionally increase the risk of Sec.ca after allogeneic HSCT, although increased risks of other diseases were noted. Physicians should carefully consider individualized risks and benefits of TBI, with a particular focus by age group.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Chungnam National Universit.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
328MO - The pivotal clinical study of IM19 CAR-T cells in the treatment of relapsed or refractory aggressive B cell non-Hodgkin lymphomas
Presenter: Yan Xie
Session: Mini oral session: Haematological malignancies
Resources:
Abstract
Slides
329MO - HLX208, a novel BRAF V600E inhibitor, in adult patients with Langerhans cell histiocytosis and/or Erdheim-Chester disease harbouring BRAF V600E mutation
Presenter: Xin-xin Cao
Session: Mini oral session: Haematological malignancies
Resources:
Abstract
Slides
Webcast
330MO - Pooled safety analysis of zanubrutinib monotherapy in Asian patients with B cell malignancies
Presenter: Won Seog Kim
Session: Mini oral session: Haematological malignancies
Resources:
Abstract
Slides
Webcast
Invited Discussant 328MO, 329MO and 330MO
Presenter: Koji Izutsu
Session: Mini oral session: Haematological malignancies
Resources:
Slides
Webcast
Q&A and discussion
Presenter: All Speakers
Session: Mini oral session: Haematological malignancies
Resources:
Webcast
331MO - Comparing data distribution and prognosis of acute myeloid leukemia according to 5th WHO classification and international consensus
Presenter: Soo Jung Lee
Session: Mini oral session: Haematological malignancies
Resources:
Abstract
Slides
Webcast
Invited Discussant 331MO and 332MO
Presenter: Michelle Poon
Session: Mini oral session: Haematological malignancies
Resources:
Slides
Webcast
Q&A and discussion
Presenter: All Speakers
Session: Mini oral session: Haematological malignancies
Resources:
Webcast
333MO - Treatment patterns in patients with mantle cell lymphoma: Updated report of the Asia-Pacific multinational retrospective registry study
Presenter: Dok Hyun Yoon
Session: Mini oral session: Haematological malignancies
Resources:
Abstract
Slides
Webcast
334MO - A multicenter retrospective study to understand the clinical characteristics, treatment patterns, and outcomes of CLL patients in the Middle East: A subgroup analysis of the CREEK study
Presenter: Raafat Mohamed Abdelfattah Soliman
Session: Mini oral session: Haematological malignancies
Resources:
Abstract
Slides
Webcast